Beautiful Virgin Islands

Thursday, Oct 09, 2025

AstraZeneca's pledge to poorer nations as it seeks COVID jab profits from next year

AstraZeneca's pledge to poorer nations as it seeks COVID jab profits from next year

The pharmaceutical company's chief executive defends the company's decision to start making profits from its COVID-19 vaccine, saying that countries with "low purchasing power" will be spared.

The chief executive of AstraZeneca (AZ) has told Sky News that the company's decision to begin seeking a modest profit from its COVID vaccine is unlikely to kick in until next year.

Pascal Soriot said this was because it still had many doses of the jab to supply that it had promised to do so at cost.

AZ announced earlier this month that it would be seeking to achieve a modest profit in future from the vaccine, in order to fund its new anti-viral COVID treatment.

The company's initial strategy was to provide the jab at cost, designed to help poorer countries get supplies, but the vaccine was also the backbone of the UK's early rollout to older people in late 2020 and early 2021.

But Mr Soriot stressed that, while some countries would be charged above cost for the vaccine, many more would not.
Advertisement

He said: "You have to remember that the orders we are taking today will be delivered next year. We still have a lot of orders at no profit to deliver. So they will be delivered next year.

"So you have got to think of the infection as if you were already in next year. And so essentially most of the world at that point will be in a different phase. And we will be more in a regional epidemic or regional pandemic than a global pandemic.

"But you know, we will of course adapt to every circumstance and countries that have low purchasing power we will be supplied at no profit or very low price and others will be a bit more."

Mr Soriot insisted that he had no regrets that AZ had provided the vaccine at cost, even though some of its competitors, such as Pfizer and Moderna, have supercharged their profits through charges for their COVID vaccines.

He went on: "We always knew that some vaccines would be sold at a profit and we made the decision from day one that we would partner with Oxford and deliver this vaccine around the world at no profit so everybody could access it much as possible.

Vials of COVID vaccines made by AstraZeneca, Pfizer, Johnson and Johnson, and Sputnik V


"And again, we've delivered more than 2 billion doses, 30% of global supply so far, so it really has worked quite well actually. So we always knew that it was what we were going to do. So there is no surprise, so there can't be any regret - it was our plan all along."

Mr Soriot also played down criticism that AZ had received during the pandemic from politicians in Europe, such as the French president Emmanuel Macron, who in January this year claimed that the company's vaccine was "quasi ineffective" in the over-65s.

The AZ chief executive, who declined to comment on why Mr Macron had subsequently changed his mind, suggested that, in fact, the relatively low levels of hospitalisations now being seen in the UK compared with continental Europe might be down to the use of the AZ vaccine in older people.

He noted that, in continental Europe, older patients have mainly been vaccinated with the mRNA vaccine produced by Pfizer.

Mr Soriot added: "Continental Europe vaccinated older people mostly with the mRNA vaccine and the UK vaccinated older people mostly with our vaccine - and we'll have to see over time whether that creates a difference.

"But what is really interesting to see in the data today is that in the UK, the number of hospitalisations…has remained relatively low, even though there were lots of infections, the number of severe infections and hospitalisations was still reasonable, relative to continental Europe, where the number of hospitalisations is relatively high in some countries."

He was speaking as AZ, the largest company in the FTSE 100, formally unveils The Discovery Centre, its new £1bn research and development facility in Cambridge, which will be home to some 2,200 scientists.

The centre, to be opened by the Prince of Wales today, represents the biggest single investment ever made by AZ.

It has been specifically sited in Cambridge to be at the heart of the city's life sciences cluster, within close proximity to the Royal Papworth and Addenbrookes hospitals, Cancer Research UK and the University of Cambridge's school of clinical medicine.

The site is referred to in scientific circles as the 'Nobel factory' as it has created more Nobel Prize winners than anywhere else in the world.

Mr Soriot said AZ spent around $7bn (£5.3bn) on research and development annually - of which "a large proportion", close to one third, is deployed in the UK.

He added: "It's a very substantial investment we make each year."

The opening comes at a hugely busy time for AZ which, earlier this year, completed the $39bn takeover of the rare diseases specialist Alexion.

That took the company, traditionally better known in the industry for its treatments for cancers, heart and respiratory conditions, into a fourth therapy area - and now it has decided, based on the success of its COVID vaccine roll out, to expand into a fifth, vaccines, as well.

However, asked whether AZ was trying to do too much at once, Mr Soriot insisted this was not the case.

He added: "We have great strengths in oncology and we believe we can be one of the three great companies in the world in oncology and maybe even better than that by 2025.

AZ has just achieved its first quarter of $10bn sales


"We continue to do very well in cardiovascular and bio pharmaceuticals overall and now we have rare diseases and vaccines.

"What we call the vaccine and immunotherapy unit is really looking at is managing this portfolio of products to treat or vaccinate people with viral diseases.

"We want to maximise the value of these assets and manage them better.

"Now whether we invest in the long run in this field remains to be seen, but there's a lot of synergies across this portfolio of products."

Mr Soriot pointed out that AZ had just achieved its first quarter during which it had notched up $10bn worth of sales.

It is a significant milestone because, when Mr Soriot oversaw AZ's successful defence against an unwanted takeover approach from Pfizer in 2014, he promised investors that AZ would be delivering annual sales of $40bn a year by 2023.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
France: Less Than a Month After His Appointment, the New French Prime Minister Resigns
Hungarian Prime Minister Viktor Orbán stated that Hungary will not adopt the euro because the European Union is falling apart.
Sarah Mullally Becomes First Woman Appointed Archbishop of Canterbury
Mayor in western Germany in intensive care after stabbing
Australian government pays Deloitte nearly half a million dollars for a report built on fabricated quotes, fake citations, and AI-generated nonsense.
US Prosecutors Gained Legal Approval to Hack Telegram Servers
Macron Faces Intensifying Pressure to Resign or Trigger New Elections Amid France’s Political Turmoil
Standard Chartered Names Roberto Hoornweg as Sole Head of Corporate & Investment Banking
UK Asylum Housing Firm Faces Backlash Over £187 Million Profits and Poor Living Conditions
UK Police Crack Major Gang in Smuggling of up to 40,000 Stolen Phones to China
BYD’s UK Sales Soar Nearly Nine-Fold, Making Britain Its Biggest Market Outside China
Trump Proposes Farm Bailout from Tariff Revenues Amid Backlash from Other Industries
FIFA Accuses Malaysia of Forging Citizenship Documents, Suspends Seven Footballers
Latvia to Bar Tourist and Occasional Buses to Russia and Belarus Until 2026
A Dollar Coin Featuring Trump’s Portrait Expected to Be Issued Next Year
Australia Orders X to Block Murder Videos, Citing Online Safety and Public Exposure
Three Scientists Awarded Nobel Prize in Medicine for Discovery of Immune Self-Tolerance Mechanism
OpenAI and AMD Forge Landmark AI-Chip Alliance with Equity Option
Munich Airport Reopens After Second Drone Shutdown
France Names New Government Amid Political Crisis
Trump Stands Firm in Shutdown Showdown and Declares War on Drug Cartels — Turning Crisis into Opportunity
Surge of U.S. Billionaires Transforms London’s Peninsula Apartments into Ultra-Luxury Stronghold
Pro Europe and Anti-War Babiš Poised to Return to Power After Czech Parliamentary Vote
Jeff Bezos Calls AI Surge a ‘Good’ Bubble, Urges Focus on Lasting Innovation
Japan’s Ruling Party Chooses Sanae Takaichi, Clearing Path to First Female Prime Minister
Sean ‘Diddy’ Combs Sentenced to Fifty Months in Prison Following Prostitution Conviction
Taylor Swift’s ‘Showgirl’ Launch Extends Billion-Dollar Empire
Trump Administration Launches “TrumpRx” Plan to Enable Direct Drug Sales at Deep Discounts
Trump Announces Intention to Impose 100 Percent Tariff on Foreign-Made Films
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Singapore and Hong Kong Vie to Dominate Asia’s Rising Gold Trade
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Manhattan Sees Surge in Office-to-Housing Conversions, Highest Since 2008
Switzerland and U.S. Issue Joint Assurance Against Currency Manipulation
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Thomas Jacob Sanford Named as Suspect in Deadly Michigan Church Shooting and Arson
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
New York Man Arrested After On-Air Confession to 2017 Parents’ Murders
U.S. Defense Chief Orders Sudden Summit of Hundreds of Generals and Admirals
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
Trump Claims FBI Planted 274 Agents at Capitol Riot, Citing Unverified Reports
India: Internet Suspended in Bareilly Amid Communal Clashes Between Muslims and Hindus
Supreme Court Extends Freeze on Nearly $5 Billion in U.S. Foreign Aid at Trump’s Request
Archaeologists Recover Statues and Temples from 2,000-Year-Old Sunken City off Alexandria
China Deploys 2,000 Workers to Spain to Build Major EV Battery Factory, Raising European Dependence
Speed Takes Over: How Drive-Through Coffee Chains Are Rewriting U.S. Coffee Culture
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Ringo Starr Champions Enduring Beatles Legacy While Debuting Las Vegas Art Show
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
×